J. Pharm. Tech. Res. Management Vol. 12, No. 1 (2024), pp.91–93

CHITKARA

Journal of Pharmaceutical Technology Research and Management
Journal homepage: https://jptrm.chitkara.edu.in/

Use of Artificial Intelligence in Molecular Pharmacology

Amarjot Kaur Grewal

Chitkara College of Pharmacy, Chitkara University, Punjab, India.

*amarjot.kaur@chitkara.edu.in (Corresponding Author)

EDITORIAL INFORMATION

Received: 05 April, 2024
Published Online: 20 April, 2024

Keywords:
Artificial Intelligence (AI) in Drug Discovery, Molecular pharmacology, Machine learning, Deep learning, Predictive modeling, Personalized medicine

DOI: 10.15415/jptrm.2024.121008

Dear Colleagues

Over the last few years, artificial intelligence (AI) has emerged as a robust force in biomedical research, and especially in drug development—an inherently complex but fundamentally important area, where efficiency and effectiveness have been major barriers in the past. With the transformational capabilities in molecular pharmacology, AI is helping revolutionize research by offering molecular pharmacology on virtual screening of chemical libraries, *de novo* drug design, molecular interactions, prediction of pharmacokinetic properties, prediction of drug target interactions, prediction of toxicities, patient stratification, clinical trial optimization, improved molecular structures, and potential side effects. These algorithms can help cascade the identification of lead compounds and optimization of the therapeutic candidate through the drug development process. Using traditional methods, it is difficult to identify the complex interplay of molecules and pathways in diseases. Making drug development more efficient and cost-effective, traditional pharmacological approaches are transforming to the use of AI algorithms for analyzing massive biological datasets and modeling complex biological systems like genomics and proteomics to identify disease-associated targets and predict interaction with potential drug candidates using network analysis tools and graph neural networks. Gene expression changes in diseased cells can be analyzed using AI in identifying novel drug targets and identifying the critical pathways for intervention. By using this approach to drug discovery, the likelihood of successful drug approvals is increased, and it decreases the development cost. This is clearly a time of integration between AI and molecular pharmacology as we see the integration of AI in key aspects of drug discovery and development, each contributing to the acceleration and precision of these processes. By using AI, drug targets can be identified, and lead compounds can be optimized virtually through virtual screening and *de novo* drug design. Molecular structures and interactions are predicted using techniques such as machine learning (ML) and deep learning (DL), which significantly reduce the time and cost required by traditional drug discovery methods. The design of such drugs can be enhanced and adverse effects minimized by using AI. The approach called targeted polypharmacology uses AI to model protein structures and predict polypharmacological effects, providing a systematic way to design a multi-target drug. Predictive models driven by AI were used to predict pharmacokinetic properties (absorption, distribution, metabolism, excretion, and toxicity, ADME/T) during the drug development process and predetermine safer and more effective drugs. It decreases the chances of failure in later clinical stages. Researchers have developed a methodology to use the AI-PBPK platform to predict PK and PD outcomes for candidate compounds in early-stage drug discovery. A mechanism-based PD model, which predicts PD outcomes based on PK results, is

ISSN No.: 2321-2217(Print) ISSN No.: 2321-2225(Online); Registration No. : CHAENG/2013/50088

used across with machine learning to estimate model parameters for this comprehensive platform. Machine learning and deep learning have now been used throughout many stages of the drug discovery pipeline. Virtual screening, activity scoring, and the prediction of quantitative structure activity relationship (QSAR) are included in this. Specifically, deep learning methods have been made useful for predicting the molecular properties, as well as generating new molecules. In clinical pharmacology, AI is used in target identification, generative chemistry in small molecule drug discovery, and in the evaluation of clinical trial outcomes. By integrating heterogeneous data into a comprehensive model, AI-driven approaches can help streamline the drug development process, improve decision-making, speed up, and decrease the cost of clinical trials. This also applies to personalized medicine, which uses real-world patient data to analyze with AI in order to improve treatment outcomes and increase patient adherence. As artificial intelligence and molecular pharmacology come together, predictive modeling will move to new levels. Drug development has relied heavily on AI to improve efficiency and effectiveness. AI algorithms use analysis of large biological datasets to improve predictions of drug target interactions. Traditional machine learning and large datasets; network-based models with the combination of various biological data; and deep learning architectures like Convolutional Neural Networks (CNN), Graph Convolutional Networks (GNN), and Transformers all have their set of strengths towards modeling the molecular interactions. Meanwhile, it is found that biological networks are useful for association-based prediction methods to identify potential drug targets, with algorithms such as CIPHER and Drug CIPHER showing promising results. In particular, prediction accuracy is improved by deep learning applications, such as CNNs for spatial patterns, GCNs for relational data, and Transformers for complex dependencies. Molecular collision-based predictions use traditional and deep learning models along with CNNs and GCNs that improve the accuracy by keeping structural information. Network-based and deep learning algorithms like NIMS and Match Maker are used to predict drug combinations that would yield a synergistic effect. G protein-coupled receptors (GPCRs) provide a wider overview about how the use of AI and ML techniques can improve drug discovery. Machine learning and AI have been applied to many areas of GPCR research, including GPCR classification, prediction of GPCR activation level, modeling GPCR 3D structure and interaction, G-protein selectivity understanding, elucidating the structure of the GPCRs, and drug design. In molecular pharmacology, resveratrol's therapeutic mechanism in rheumatoid arthritis (RA) is predicted using artificial intelligence. Gene expression data were analyzed in pharmacophore target networks, as well as by gene functional enrichment analysis using AI-driven bioinformatics tools. Using protein-protein interaction network analysis, key therapeutic genes (KT-genes) were identified, and their structures were predicted by AlphaFold. Resveratrol's binding affinities to these targets were confirmed by molecular docking simulations. It has been found that AI improved drug mechanism understanding and sped up drug discovery with insights into beating complex diseases like RA. Though the use of AI for molecular pharmacology comes with its challenges. The advancements in molecular pharmacology using AI come at a price, as the model needs to be robust and also the ethical concerns. They struggle to train AI models unless they have enough high-quality data; however, they do not always have access in certain areas of drug discovery. AI-based predictions in drug development have to be validated carefully with respect to regulatory requirements and so on. However, it is difficult to understand how AI models come to their predictions, and that hinders the translation of findings into clinical practice. They are essential for the continued integration of AI into pharmacology to ensure the reliability and applicability of AI-driven predictions in biological situations that are varied. Physically explaining predictions is important for regulatory approval and clinical acceptability, but its complexity makes it difficult to provide physically interpretable explanations for AI models. In particular, given the use of large language models, the dual-use nature of AI also has ethical concerns about the threat of misusing AI for bioweapon development. Transparency, accountability, and safety necessitate robust regulations, ethical guidelines, and technical solutions. Molecular pharmacology is in the future of AI, and as the technology continues to improve over the next few years, AI is going to push the boundaries of molecular drug discovery even more. Although AI does show great potential for human and societal benefit, it also presents major risks that must be managed, and these continue to be mitigated by economic and regulatory incentives to invest in AI research and development, whereas comprehensive regulatory frameworks are currently lacking. Finally, AI is enabling the speed and efficiency improvements, as well as improving accuracy in drug discovery and development in the field of molecular pharmacology. The AI paradigm is still developing and running into challenges related to ethics and model interpretability; however, there is great promise for the future of pharmacology with the continued development of AI technologies.

Journal of Pharmaceutical Technology, Research and Management

Chitkara University, Saraswati Kendra, SCO 160-161, Sector 9-C, Chandigarh, 160009, India

Volume 12, Issue 1 **April 2024** **ISSN 2321-2217**